





Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis

Edited by Achille G. Gravanis
and Synthia H. Mellon



 WILEY-
BLACKWELL

Edited by
Achille G. Gravanis and
Synthia H. Mellon

**Hormones in Neurodegeneration,
Neuroprotection, and Neurogenesis**

Related Titles

Kvetnansky, R., Aguilera, G., Goldstein, D.,
Jezova, D., Krizanova, O., Sabban, E.,
Pacak, K.

Stress, Neurotransmitters, and Hormones

Neuroendocrine and Genetic Mechanisms

2009

ISBN: 978-1-57331-692-7

Nothwang, H., Pfeiffer, E (eds.)

Proteomics of the Nervous System

2008

ISBN: 978-3-527-31716-5

Bader, M. (ed.)

Cardiovascular Hormone Systems

**From Molecular Mechanisms to Novel
Therapeutics**

2008

ISBN: 978-3-527-31920-6

von Bohlen und Halbach, O.,
Dermietzel, R.

Neurotransmitters and Neuromodulators

**Handbook of Receptors and
Biological Effects**

2006

ISBN: 978-3-527-31307-5

Cutolo, M., Bijlsma, J. W. J., Straub, R. H.,
Masi, A. T. (eds.)

Neuroendocrine Immunology in Rheumatic Diseases

Translation from Basics to Clinics

2010

ISBN: 978-1-57331-769-6

Edited by Achille G. Gravanis and Synthia H. Mellon

Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis



**WILEY-
BLACKWELL**

WILEY-VCH Verlag GmbH & Co. KGaA

The Editors

Prof. Dr. Achille G. Gravanis
Dept. of Pharmacology
Univ. of Crete Med. School
71110 Heraklion
Greece

Prof. Dr. Synthia H. Mellon
Ctr. Reproductive Sciences
University of California
P.O. Box 0556
San Francisco, CA 94143-0556
USA

Cover

The cover photo depicts sympathetic neurons in culture, isolated from superior cervical ganglia (SCG) of E17 mouse embryos (With kind permission from the Dept. of Pharmacology, School of Medicine, University of Crete).

Limit of Liability/Disclaimer of Warranty:

While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty can be created or extended by sales representatives or written sales materials. The Advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2011 WILEY-VCH Verlag & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical, and Medical business with Blackwell Publishing.

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Cover Design Formgeber, Eppelheim

Typesetting Laserwords Private Limited, Chennai, India

Printing and Binding Fabulous Printers Pte Ltd, Singapore

Printed in Singapore

Printed on acid-free paper

ISBN: 978-3-527-32627-3

Foreword

To the scientific keywords of this book, I certainly like to add “ageing” and “hope.” Clearly, the main risk of neurodegeneration is increased lifespan, which characterizes the current evolution of mankind and, at the same time, today we have hope and even some remedies for improved understanding and means of maintaining active brain function until we die.

The CNS receives, modulates, and transfers to the body information from the environment; it controls our mental and affective life and is therefore largely in command of our behavior and activities. The hormonal system (which includes more than 50 distinct important molecules) is the main vector of the CNS, which gives orders to the rest of the body. Conversely, many hormones synthesized at the “periphery” have access to the brain and can modify its (re)actions. Hormones interact between them at levels of regulated synthesis, metabolism and activities. Age-dependent changes in secretion, distribution, receptors, and metabolism of hormones are important to study; they may be responsible for opposite effects according to the “age.” If the core of the receptors’ structure is the same in most target cells, the receptor-associated proteins vary according to the tissue, physiological state, and so on, including the age of the person.

The CNS is certainly the most complex system of our body. With reference to hormones, not only does it control many glandular productions and therefore their activities, but it itself also synthesizes some of them already produced by peripheral glands, such as in the case of neurosteroids. For example [1], progesterone, made in Schwann cells and oligodendrocytes, is obviously the same as the progesterone coming from ovaries; it is, however, understandable that it works preferentially (probably or even uniquely) in the neighboring nerves and myelin, we even know that “classical” glandular progesterone may have the same activities. Does this double origin influence an important secondary sex characteristic explaining the pathological differences between men and women? Up to now, we believe that “neuroprogesterone” does not act through receptors different from those found at the periphery (nuclear receptors).

Among neurosteroids (synthesized in the CNS by definition) [2], pregnenolone is globally the most abundant, and it itself displays activities in the CNS, which have not yet been demonstrated elsewhere in the organism. MAP2, an important

microtubule-associated protein abundant in the brain, is a pregnenolone receptor, binding the steroid specifically, thus stimulating tubulin polymerization [3]. Its derivative “MAP4343,” which is not metabolized to progesterone, is active to treat spinal cord injuries (European patent EP15831538, 2008). In addition, pregnenolone, when sulfated at the 3-position, becomes a ligand of the GABA_A receptor, antagonist to allopregnanolone, and also an active ligand of an NMDA receptor [4].

The steroid receptors bind reversibly to the heat shock protein HSP90, and while working on the hetero-oligomeric forms of these receptors, an immunophilin (binding immunosuppressants) protein FKBP52 was discovered. This protein, abundant in the brain, is able to bind to Tau (a microtubule-associated protein) and display an “anti Tau effect” on Tau activity on tubulin polymerization [5]. These results deriving from hormonal studies (even without direct action of steroids) have led to unveil novel mechanisms applicable to neurodegenerative diseases (whether hormones will or will not additionally interfere has not been detected so far).

The previously cited examples make logical that this book includes a remarkable variety of functions for hormones acting, from and/or for, on the CNS. An incomplete list includes the interesting actions of estrogens; progesterone (and progestins); androgens themselves or in association with peptides of the insulin-growth hormone – IGF family; the role of leptin; the subtle and varied effects of glucocorticosteroids and dehydroepiandrosterone; and the effects of somatostatin, CRH, PACAP, and erythropoietin. No doubt therapeutic issues may arise from these studies. Hormonal activities can be manipulated at the level of production (an example with etifoxine stimulating the neurosteroid pregnenolone production) [6], at the level of receptors (hormone antagonists), and at the level of their metabolism (via transport protein function and hepatic and renal functions).

I take the liberty to advise the readers of the book to keep it near their desk: they will have the privilege to conveniently obtain information on “new neuroendocrinology” as well as on appropriate references of talented authors of the reports.

Kremlin–Bicêtre, November 2010

Etienne Emile Baulieu

References

1. Koenig, H.L., Schumacher, M., Ferzaz, B., Do Thi, A.N., Ressouches, A., Guennoun, R., Jung-Testas, I., Robel, P., Akwa, Y., and Baulieu, E.E. (1995) Progesterone synthesis and myelin formation by Schwann cells. *Science* **268**, 1500–1503.
2. Baulieu, E.E. (1997) in *Recent Progress in Hormone Research* vol. 52 (ed. P.M. Conn), The Endocrine Society Press, Bethesda, pp. 1–32.
3. Fontaine-Lenoir V., Chambraud B., Fellous A., David S., Duchossoy Y., Baulieu E.E., and Robel P. (2006) Microtubule-associated protein 2 (MAP2) is a neurosteroid receptor. *Proc. Natl. Acad. Sci. USA.*, **103**, 4711–4716.
4. Baulieu, E.E., Robel, P., and Schumacher, M. (eds) (1999) *Neurosteroids. A new regulatory function in the nervous system*. Humana Press, Totowa, New Jersey.

5. Chambraud B., Sardin E., Giustiniani J., Dounane O., Schumacher M., Goedert M., and Baulieu E.E. (2010) A role for FKBP52 in Tau protein function. *Proc. Natl. Acad. Sci. USA.*, **107**, 2658–2663.
6. Girard C., Liu S., Cadepond F., Adams D., Lacroix C., Verleye M., Gillardin J.M., Baulieu E.E., Schumacher M., and Schweizer-Groyer G. (2008) Etifoxine improves peripheral nerve regeneration and functional recovery. *Proc. Natl. Acad. Sci. USA.*, **105**, 20505–20510.

Contents

List of Contributors XIX

Part I Estrogens, Progestins, Allopregnanolone and Neuroprotection 1

1 Interactions of Estradiol and Insulin-like Growth Factor-I in Neuroprotection: Implications for Brain Aging and Neurodegeneration 3

María-Angeles Arévalo, Luis M. Garcia-Segura, and Iñigo Azcoitia

- 1.1 Introduction: Hormones, Brain Aging, and Neurodegeneration 3
- 1.2 Estradiol, IGF-I, Brain Aging, and Neuroprotection 4
- 1.3 Molecular Interactions of Estrogen Receptors and IGF-I Receptor in the Brain 5
- 1.4 Regulation of IGF-I Receptor Signaling by Estradiol in the Brain 5
- 1.5 Regulation of Estrogen Receptor Transcriptional Activity by IGF-I in Neural Cells 6
- 1.6 Implications of the Cross Talk between Estrogen Receptors and IGF-I Receptors for Brain Aging, and Neurodegeneration 6
- Acknowledgment 8
- References 8

2 Structure–Nongenomic Neuroprotection Relationship of Estrogens and Estrogen-Derived Compounds 13

James W. Simpkins, Kun Don Yi, Evelyn Perez, and Douglas Covey

- 2.1 Introduction 13
- 2.2 *In vitro* Assessments of Structure–Neuroprotective Activity Relationships 14
 - 2.2.1 Estradiol and Other Known Estratrienes 15
 - 2.2.2 A-Ring Derivatives 15
 - 2.2.3 B- and C-Ring Derivatives 16
 - 2.2.4 D-Ring Derivatives 17
 - 2.2.5 Correlation between Inhibition of TBARs and Protection against Glutamate and IAA 17
 - 2.2.6 Estrogen Receptor Binding 17

2.2.7	Correlation between Inhibition of TBARs or Neuroprotection and ER Binding	18
2.2.8	Interpretation of <i>In vitro</i> Findings	19
2.3	<i>In vivo</i> Assessment of Structure–Neuroprotective Activity Relationships	20
2.4	<i>In vitro</i> Assessment of Structure–Cell Signaling Relationships	20
2.5	Summary	24
	Acknowledgment	24
	References	24
3	Progesterins and Neuroprotection: Why the Choice of Progesterin Matters	29
	<i>Meharvan Singh</i>	
3.1	Introduction	29
3.2	The Biology of Progesterone	30
3.3	Membrane-Associated Progesterone Receptors	31
3.4	Progesterone-Induced Protection	32
3.5	Mechanisms Underlying Progesterone’s Protective Effects	33
3.6	Medroxyprogesterone Acetate	34
	Acknowledgments	37
	References	37
4	Endogenous and Synthetic Neurosteroids in the Treatment of Niemann–Pick Type C Disease	41
	<i>Synthia H. Mellon, Wenhui Gong, and Marcus D. Schonemann</i>	
4.1	Introduction	41
4.2	Niemann–Pick Type C Disease as a Model of Disrupted Neurosteroidogenesis	43
4.3	Steroidogenesis and Neurosteroidogenesis in NP-C	44
4.4	Treatment of NP-C Mice with Allopregnanolone	45
4.5	Mechanism of Allopregnanolone Action: GABA _A Receptor	46
4.6	Mechanism of Allopregnanolone Action: Pregnane-X Receptor	48
4.7	Mechanism of Allopregnanolone Action: Reduction of Cellular Oxidative Stress	48
4.8	Conclusions – Mechanisms of Allopregnanolone Action in Treatment of NP-C and Other Neurodegenerative Diseases	49
	Acknowledgments	51
	References	51
Part II	Glucocorticoids, Dehydroepiandrosterone, Neuroprotection and Neuropathy	61
5	Glucocorticoids, Developmental “Programming,” and the Risk of Affective Dysfunction	63
	<i>Bayanne Olabi and Jonathan Seckl</i>	
5.1	Introduction to Programming	64

5.2	Programming	65
5.2.1	Epidemiology	65
5.2.2	Birth Weight and Neuropsychiatric Disorders	66
5.3	Glucocorticoids and Fetal Development	66
5.4	Glucocorticoids: the Endocrine Programming Factor	68
5.4.1	Placental 11 β -HSD2: a Barrier to Maternal Glucocorticoids	69
5.4.2	Glucocorticoid Programming	70
5.4.3	Transgenerational Effects	71
5.4.4	The Placenta	71
5.4.5	A Common Mechanism?	71
5.5	Fetal Tissue Glucocorticoid Sensitivity	72
5.6	Stress and Glucocorticoids: Key Programmers of the Brain	74
5.6.1	Programming the HPA Axis	74
5.6.2	Sex-Specific Effects	75
5.6.3	Programming Behavior	75
5.7	CNS Programming Mechanisms	76
5.7.1	The GR Gene: a Common Programming Target?	77
5.7.2	Epigenetics	78
5.8	Glucocorticoid Programming in Humans	78
5.8.1	Clinical Use of Prenatal Glucocorticoid Therapy	78
5.8.2	Consequences of Human Fetal Glucocorticoid Overexposure	79
5.8.3	Programming and Posttraumatic Stress Disorder (PTSD)	80
5.8.4	Programming Other Glucocorticoid Metabolizing Enzymes	81
5.9	Future Perspectives and Therapeutic Opportunities	82
5.10	Overview	83
	References	84
6	Regulation of Structural Plasticity and Neurogenesis during Stress and Diabetes; Protective Effects of Glucocorticoid Receptor Antagonists	103
	<i>Paul J. Lucassen, Carlos P. Fitzsimons, Erno Vreugdenhil, Pu Hu, Charlotte Oomen, Yanina Revsin, Marian Joëls, and Edo Ronald de Kloet</i>	
6.1	The Stress Response	103
6.2	HPA Axis and Glucocorticoids	104
6.3	Glucocorticoid Actions	104
6.4	Feedback Regulation	104
6.5	Stress and Depression	105
6.6	Stress-Induced Viability Changes in the Hippocampus: Effect on Function, Volume, Cell Number, and Apoptosis	106
6.7	Effects of Stress on Dendritic Atrophy, Spine, and Synaptic Changes	107
6.8	Adult Hippocampal Neurogenesis	107
6.9	Effect of Stress on Adult Hippocampal Neurogenesis	109
6.10	Normalization of the Effects of Stress on the Hippocampus by Means of GR Blockade	110

- 6.11 Normalization of Hippocampal Alterations during Diabetes Mellitus Using the GR Antagonist Mifepristone 113
- 6.12 Concluding Remarks 115
 - Acknowledgments 115
 - Disclosure 115
 - References 116

- 7 Neuroactive Steroids and Peripheral Neuropathy 121**
 - Roberto C. Melcangi, Silvia Giatti, Marzia Pesaresi, Donatella Caruso, and Marc J. Tetel*
 - 7.1 Introduction 121
 - 7.2 Regulation of Neuroactive Steroid Responsiveness in Peripheral Nerves 122
 - 7.2.1 Synthesis and Metabolism of Neuroactive Steroids 122
 - 7.2.2 Classical and Nonclassical Steroid Receptors are Expressed in Peripheral Nerves 123
 - 7.3 Schwann Cell Responses to Neuroactive Steroids 123
 - 7.4 Sexually Dimorphic Changes of Neuroactive Steroid Levels Induced by Pathology in Peripheral Nerves 126
 - 7.5 Neuroactive Steroids as Protective Agents in PNS 126
 - 7.5.1 Aging Process 126
 - 7.5.2 Physical Injury 127
 - 7.5.3 Diabetic Neuropathy 128
 - 7.6 Chemotherapy-Induced Peripheral Neuropathy 128
 - 7.7 Concluding Remarks 129
 - Acknowledgments 129
 - References 129

- 8 Neuroprotective and Neurogenic Properties of Dehydroepiandrosterone and its Synthetic Analogs 137**
 - Ioannis Charalampopoulos, Iakovos Lazaridis, and Achille Gravanis*
 - 8.1 Introduction 137
 - 8.2 Neuroprotective and Neurogenic Effects of DHEA in Hippocampal Neurons 138
 - 8.3 Neuroprotective Effects of DHEA in Nigrostriatal Dopaminergic Neurons 140
 - 8.4 Neuroprotective Effects of DHEA in Autoimmune Neurodegenerative Processes 141
 - 8.5 Neuroprotective Effects of DHEA against Brain Ischemia and Trauma 142
 - 8.6 Signaling Pathways Involved in the Effects of DHEA on Neuronal Cell Fate 144
 - 8.7 Therapeutic Perspectives of DHEA and its Synthetic Analogs in Neurodegenerative Diseases 146
 - References 147

- 9 Neurosteroids and Pain 155**
Christine Patte-Mensah, Laurence Meyer, Véronique Schaeffer, Cherkaouia Kibaly, and Ayikoe G. Mensah-Nyagan
- 9.1 Introduction 155
- 9.2 General Background on Neurosteroids 155
- 9.3 Overview on Pain 156
- 9.4 Involvement of Endogenous Neurosteroids in the Control of Pain 157
- 9.4.1 Evidence for the Local Production of Neurosteroids in the Spinal Circuit 157
- 9.4.2 Endogenous Neurosteroids and Pain Modulation 162
- 9.5 Conclusion 164
- Acknowledgments 164
- References 164
- Part III Polypeptide Hormones and Neuroprotection 171**
- 10 The Insulin/IGF-1 System in Neurodegeneration and Neurovascular Disease 173**
Przemyslaw (Mike) Sapieha and Lois Smith
- 10.1 Introduction 173
- 10.2 Insulin and Insulin Growth Factors 174
- 10.3 Local versus Systemic Actions 174
- 10.4 Insulin/IGF Signaling Pathway 175
- 10.5 The Insulin/IGF Axis in the Brain 176
- 10.6 Insulin/IGF and Neuroprotection 176
- 10.7 Alzheimer's Disease 178
- 10.8 Parkinson's Disease 179
- 10.9 Vascular Dementia 179
- 10.10 Neurovascular Degeneration 180
- 10.11 Conclusion 182
- References 182
- 11 Leptin Neuroprotection in the Central Nervous System 189**
Feng Zhang, Suping Wang, Armando P. Signore, Zhongfang Weng, and Jun Chen
- 11.1 Introduction 189
- 11.1.1 Origin, Source, and Structure of Leptin 189
- 11.1.2 Functions of Leptin 189
- 11.1.3 Leptin Receptors 190
- 11.1.4 Leptin Transport across the Blood–Brain Barrier 191
- 11.2 Mutation of Leptin or Leptin Receptors 192
- 11.3 Neurotrophic Role of Leptin 193
- 11.4 Leptin Neuroprotection against Disorders of the Central Nervous System 193
- 11.4.1 Acute Neurological Disorders 193

- 11.4.2 Neurodegenerative Diseases and Other Disorders 196
- 11.4.3 Leptin Neuroprotective Mechanisms 199
- 11.5 Significance 199
- References 199

- 12 Somatostatin and Neuroprotection in Retina 205**
Kyriaki Thermos
- 12.1 Introduction 205
- 12.2 Somatostatin and Related Peptides 206
- 12.3 Somatostatin Receptors and Signaling 206
- 12.4 Somatostatin and its Receptors in Retina 206
- 12.5 Localization of Somatostatin Receptors in Retinal Neurons 207
- 12.5.1 Sst₁ 208
- 12.5.2 Sst₂ 208
- 12.5.3 Sst₃ 209
- 12.5.4 Sst₄ 209
- 12.5.5 Sst₅ 209
- 12.6 Somatostatin Receptor Function in Retinal Circuitry 209
- 12.6.1 Effects on Glutamate Release 210
- 12.6.2 Effects on Dopamine Release 210
- 12.6.3 Effects on Nitric Oxide/GMP 210
- 12.6.4 Effects on Somatostatin Release 211
- 12.7 Neuroprotection by Somatostatin Analogs 212
- 12.7.1 Retinal Ischemia and Excitotoxicity 212
- 12.7.2 Anti-Ischemic Actions of SRIF 212
- 12.7.2.1 *Ex vivo* Studies 212
- 12.7.2.2 *In vivo* Studies 213
- 12.8 Mechanisms of SRIF's Neuroprotection 213
- 12.8.1 Involvement of NO/cGMP 213
- 12.8.2 NO/cGMP Mediates SRIF's Neuroprotective Effects 214
- 12.9 Therapeutic Potential of Somatostatin Agents 216
- 12.10 Conclusions 217
- Acknowledgments 217
- Abbreviations 218
- References 218

- 13 Neurotrophic Effects of PACAP in the Cerebellar Cortex 227**
Anthony Falluel-Morel, Hubert Vaudry, Hitoshi Komuro, Dariusz C. Gorecki, Ludovic Galas, and David Vaudry
- 13.1 Expression of PACAP and its Receptors in the Developing Cerebellum 227
- 13.2 Effects of PACAP on Granule Cell Proliferation 229
- 13.3 Effects of PACAP on Granule Cell Migration 229
- 13.4 Effects of PACAP on Granule Cell Survival 231

- 13.5 Effects of PACAP on Granule Cell Differentiation 231
- 13.6 Functional Relevance 233
- Acknowledgments 234
- References 234
- 14 The Corticotropin-Releasing Hormone in Neuroprotection 237**
Christian Behl and Angela Clement
- 14.1 Introduction 237
- 14.2 The CRH Family of Proteins and Molecular Signal Transduction 238
- 14.3 From the Physiology to the Pathophysiology of CRH 239
- 14.4 CRH and Neurodegenerative Conditions 240
- 14.5 Protective Activities of CRH 240
- 14.6 Lessons from the Heart 244
- 14.7 Outlook 245
- References 245
- 15 Neuroprotective and Neurogenic Effects of Erythropoietin 251**
Helmar C. Lehmann and Ahmet Höke
- 15.1 Introduction 251
- 15.2 EPO in Models of Neonatal Hypoxic-Ischemic Brain Injury 251
- 15.3 EPO in Models of Ischemic Stroke in Adults 253
- 15.4 EPO in Models of Traumatic Brain Injury and Spinal Cord Trauma 257
- 15.5 EPO in Experimental Autoimmune Encephalomyelitis 257
- 15.6 EPO in Models of Peripheral Neuropathy 258
- 15.7 Summary 260
- References 260
- Part IV Hormones and Neurogenesis 265**
- 16 Thyroid Hormone Actions on Glioma Cells 267**
Min Zhou, Harold K. Kimelberg, Faith B. Davis, and Paul J. Davis
- 16.1 Introduction 267
- 16.2 Origins of Glioma 267
- 16.3 Glioma Cell Biology 268
- 16.4 Thyroid Hormone Analogs, Transport, and Metabolism 270
- 16.5 Thyroid Hormones and Brain Development 270
- 16.6 Nongenomic Actions of Thyroid Hormones 271
- 16.7 Hypothyroidism Suppresses Growth of Glioma in Patients 273
- 16.8 Molecular Mechanisms of Hypothyroidism-Induced Clinical Suppression of Glioma Progression 273
- 16.8.1 Thyroid Hormone and Proliferation of Tumor Cells 274

- 16.8.2 Angiogenic Action of Thyroid Hormones 274
- 16.8.3 Antiapoptotic Action of Thyroid Hormones 274
- 16.8.4 Tumor Suppression Actions of Tetrac 275
- 16.9 Future Perspectives 275
- References 276

- 17 Gonadal Hormones, Neurosteroids, and Clinical Progestins as Neurogenic Regenerative Agents: Therapeutic Implications 281**
Lifei Liu and Roberta Diaz Brinton
- 17.1 Introduction 281
- 17.2 Gonadal Hormones, Neurosteroids, and Neurogenesis 282
 - 17.2.1 Ovarian Hormone Regulation of Adult Neurogenesis 284
 - 17.2.2 Estrogen Regulation of Adult Neurogenesis 284
 - 17.2.3 Progesterone Regulation of Adult Neurogenesis 286
 - 17.2.4 Progesterone Regulation of Adult Neurogenesis 287
 - 17.2.5 Clinical Progestin Regulation of Neurogenesis 287
 - 17.2.6 Androgen Regulation of Adult Neurogenesis 288
 - 17.2.7 Testosterone and DHT Regulation of Adult Neurogenesis 288
 - 17.2.8 DHEA Regulation of Adult Neurogenesis 289
- 17.3 Neurosteroid Regulation of Adult Neurogenesis 290
 - 17.3.1 Pregnenolone and Pregnenolone Sulfate Regulation of Adult Neurogenesis 290
 - 17.3.2 Allopregnanolone Regulation of Adult Neurogenesis 291
- 17.4 Gonadal Steroids, Clinical Progestins, and Neurosteroids as Neuroregenerative Therapeutics: Challenges and Strategies 292
 - 17.4.1 Targeting Neurogenesis as a Treatment for Neurodegenerative Disease 293
 - 17.4.2 AP α as a Regenerative Factor to Promote Functional Neurogenesis and Diminish Alzheimer's Pathology 294
 - References 295

- 18 Gonadotropins and Progestogens: Obligatory Developmental Functions during Early Embryogenesis and their Role in Adult Neurogenesis, Neuroregeneration and Neurodegeneration 305**
Craig S. Atwood and Sivan Vadakkadath Meethal
- 18.1 Introduction 305
- 18.2 Hormonal Regulation of Human Embryogenesis 305
 - 18.2.1 The Missing Links 305
 - 18.2.2 Trophoblastic Hormone Secretion 306
 - 18.2.3 Human Embryonic Stem Cells: A Complete Model System for Understanding the Cellular and Molecular Mechanisms Regulating Early Human Embryogenesis 308
 - 18.2.4 Progesterone, Human Chorionic Gonadotropin, and Early Human Embryogenesis 308

- 18.2.4.1 Regulation of Blastulation by Human Chorionic Gonadotropin and Progesterone 308
- 18.2.4.2 Regulation of Neurulation by Human Chorionic Gonadotropin and Progesterone 310
- 18.2.4.3 Regulation of Organogenesis by Human Chorionic Gonadotropin and Progesterone 312
- 18.2.5 Opioid Signaling and Early Human Embryogenesis 312
- 18.3 Progesterone: an Essential Neurotrophic Hormone during All Phases of Life 313
- 18.4 Age-Related Loss of Progesterone: Implications in the Pathophysiology of Neurodegenerative Diseases 314
 - 18.4.1 Alzheimer's Disease 315
 - 18.4.1.1 Amyloid- β Precursor Protein and Neurogenesis 315
 - 18.4.1.2 Hormonal Regulation of Neurogenesis via Modulation of A β PP Metabolism 316
 - 18.4.1.3 Progesterone in the Treatment of AD 316
 - 18.4.2 Stroke 317
- 18.5 Conclusion 318
 - References 319

- 19 Human Neural Progenitor Cells: Mitotic and Neurogenic Effects of Growth Factors, Neurosteroids, and Excitatory Amino Acids 331**
Masatoshi Suzuki, Jacalyn McHugh, and Narisorn Kitiyanant
 - 19.1 Introduction 331
 - 19.2 Neural Stem/Progenitor Cells as a Model of Human Cortical Development 331
 - 19.3 Mitotic and Neurogenic Effects of a Neurosteroid: Dehydroepiandrosterone (DHEA) 332
 - 19.4 Glutamate Enhances Proliferation and Neurogenesis in hNPCs 336
 - 19.5 Increased Neurogenic "Radial Glial"-like Cells within Human Neurosphere Cultures 338
 - 19.6 Conclusions 341
 - Acknowledgments 342
 - References 342

- 20 Corticosterone, Dehydroepiandrosterone, and Neurogenesis in the Adult Hippocampus 347**
Joe Herbert and Scarlet Bella Pinnock
 - 20.1 Background 347
 - 20.2 Glucocorticoids and Neurogenesis in the Adult Hippocampus 348
 - 20.2.1 Regulation by Corticoid Levels 348
 - 20.2.2 Regulation by the Corticoid Diurnal Rhythm 350
 - 20.2.3 Dehydroepiandrosterone (DHEA) 354
 - 20.2.4 Downstream Actions: pCREB and Wnt3a 357
 - 20.2.5 Relevance to Depression 358

20.3	Conclusion	360
	Acknowledgments	360
	References	360
	Index	367

List of Contributors

María-Angeles Arévalo

Instituto Cajal
Consejo Superior de
Investigaciones Científicas
(C.S.I.C.)
Avenida Doctor Arce 37
28002 Madrid
Spain

Craig S. Atwood

Department of Medicine
University of Wisconsin-Madison
School of Medicine and Public
Health and Geriatric Research
Education and Clinical Center
Veterans administration Hospital
2500 Overlook Terrace
Madison, WI 53705
USA

and

Case Western Reserve University
Department of Pathology
2103 Cornell Road
Cleveland, OH 44106
USA

and

School of Exercise
Biomedical and Health Sciences
Edith Cowan University
270 Joondalup Drive
Joondalup, 6027 WA
Australia

Iñigo Azcoitia

Universidad Complutense
Departamento de Biología Celular
Facultad de Biología
José Antonio Novais 2
28040 Madrid
Spain

Etienne Emile Baulieu

INSERM UMR 788
80 rue du Général Leclerc
94276 Kremlin-Bicêtre
France

Christian Behl

University Medical Center of the
Johannes Gutenberg University
Mainz
Institute for Pathobiochemistry
55099 Mainz
Germany

Roberta Diaz Brinton

University of Southern California
School of Pharmacy
Department of Pharmacology and
Pharmaceutical Sciences
Los Angeles, CA 90033
USA

Donatella Caruso

University of Milan
Department of Pharmacological
Sciences
Via Balzaretti 9
20133 Milano
Italy

Ioannis Charalampopoulos

University of Crete
Department of Pharmacology
School of Medicine
Stavrakia
71110 Heraklion
Greece

Jun Chen

University of Pittsburgh
Department of Neurology and
Center of Cerebrovascular
Disease Research
3550 Terrace St.
Pittsburgh
PA 15213
USA

Angela Clement

University Medical Center of the
Johannes Gutenberg University
Mainz
Institute for Pathobiochemistry
55099 Mainz
Germany

Douglas Covey

Washington University School of
Medicine
Department of Developmental
Biology
St. Louis, MO
USA

Faith B. Davis

Ordway Research Institute
Signal Transduction Laboratory
Albany, NY 12208
USA

Paul J. Davis

Ordway Research Institute
Signal Transduction Laboratory
Albany, NY 12208
USA

Anthony Falluel-Morel

University of Rouen
INSERM U982
Place E. Blondel
76821 Mont-Saint-Aignan
France

and

European Institute for Peptide
Research (IFRMP 23)
Place E. Blondel
76821 Mont-Saint-Aignan
France

and

International Laboratory
Samuel de Champlain
76821 Mont-Saint-Aignan
France

Carlos P. Fitzsimons

University of Amsterdam
 Centre for Neuroscience
 Swammerdam Institute of Life
 Sciences, Amsterdam
 Science Park 904, 1098 XH
 The Netherlands

and

Leiden University Division of
 Medical Pharmacology
 Leiden Amsterdam Center for
 Drug Research
 Einsteinweg 55
 2300RA Leiden
 The Netherlands

Ludovic Galas

European Institute for Peptide
 Research (IFRMP 23)
 Place E. Blondel
 76821 Mont-Saint-Aignan
 France

and

International Laboratory
 Samuel de Champlain
 76821 Mont-Saint-Aignan
 France

and

Regional Platform for Cell
 Imaging (PRIMACEN)
 IFRMP 23
 76821 Mont-Saint-Aignan
 France

Luis M. Garcia-Segura

Instituto Cajal
 Consejo Superior de
 Investigaciones Científicas
 (C.S.I.C.)
 Avenida Doctor Arce 37
 28002 Madrid
 Spain

Silvia Giatti

University of Milan
 Department of Endocrinology
 Pathophysiology and applied
 Biology
 Via Balzaretti 9
 20133 Milano
 Italy

Wenhui Gong

University of California
 Department of Obstetrics
 Gynecology, and Reproductive
 Sciences, The Center for
 Reproductive Sciences
 513 Parnassus Avenue
 San Francisco, CA 94143
 USA

Dariusz C. Gorecki

University of Portsmouth
 School of Pharmacy and
 Biomedical Sciences
 St. Michael Boulevard
 Portsmouth PO1 2DT
 UK

Achille Gravanis

University of Crete
 Department of Pharmacology
 School of Medicine
 Stavrakia
 71110 Heraklion
 Greece

Joe Herbert

University of Cambridge
Cambridge Centre for Brain
Repair
Forvie Site, Robinson Way
Cambridge CB20PY
UK

Pu Hu

University of Amsterdam
Centre for Neuroscience
Swammerdam Institute of Life
Sciences
Science Park 904
1098 XH Amsterdam
The Netherlands

and

University of Science and
Technology of China
Hefei National Laboratory for
Physical Sciences at Microscale
and Department of Neurobiology
and Biophysics
Hefei, Anhui
PR China

Ahmet Höke

Johns Hopkins University School
of Medicine
Department of Neurology and
Neuroscience
Pathology Building Room 509
600 N. Wolfe Street
Baltimore, MD 21287
USA

Marian Joëls

University of Amsterdam
Centre for Neuroscience
Swammerdam Institute of Life
Sciences
Science Park 904
1098 XH Amsterdam
The Netherlands

and

University Medical Center
Utrecht
Department Neuroscience and
Pharmacology
The Netherlands

Cherkaouia Kibaly

Université de Strasbourg
Equipe Stéroïdes
Neuromodulateurs et
Neuropathologies
Unité de Physiopathologie et
Médecine Translationnelle
Faculté de Médecine
11 rue Humann
67000 Strasbourg
France

Harold K. Kimelberg

Ordway Research Institute
Signal Transduction Laboratory
Albany, NY 12208
USA

Narisorn Kitiyanant

Mahidol University
Institute of Molecular Biosciences
Phutthamonthon 4 Rd
Nakhonpathom 73170
Thailand

Edo Ronald de Kloet

Leiden University
Division of Medical
Pharmacology
Leiden Amsterdam Center for
Drug Research
Einsteinweg 55
2300RA Leiden
The Netherlands

Hitoshi Komuro

The Cleveland Clinic Foundation
Lerner Research Institute
Department of Neurosciences
Cleveland, Ohio 44195
USA

Iakovos Lazaridis

University of Crete
Department of Pharmacology
School of Medicine
Stavrakia
71110 Heraklion
Greece

Helmar C. Lehmann

Heinrich Heine University
Düsseldorf
Department of Neurology
Moorenstrasse 5
40225 Düsseldorf
Germany

Lifei Liu

University of Southern California
School of Pharmacy
Department of Pharmacology and
Pharmaceutical Sciences
Los Angeles, CA 90033
USA

Paul J. Lucassen

University of Amsterdam
Centre for Neuroscience
Swammerdam Institute of Life
Sciences, Science Park 904
1098 XH
Amsterdam
The Netherlands

Jacalyn McHugh

The Cedars-Sinai Regenerative
Medicine Institute
8700 Beverly Blvd.
Los Angeles, CA 90048
USA

Sivan Vadakkadath Meethal

University of Wisconsin-Madison
Department of Neurological
Surgery
School of Medicine and Public
Health
600 Highland Avenue
Madison, WI 53792
USA

Roberto C. Melcangi

University of Milan
Department of Endocrinology
Pathophysiology and applied
Biology
Via Balzaretto 9
20133 Milano
Italy

Synthia H. Mellon

University of California
Department of Obstetrics
Gynecology, and Reproductive
Sciences, The Center for
Reproductive Sciences
513 Parnassus Avenue
San Francisco, CA 94143
USA

Ayikoe G. Mensah-Nyagan

Université de Strasbourg
Equipe Stéroïdes
Neuromodulateurs et
Neuropathologies
Unité de Physiopathologie et
Médecine Translationnelle
Faculté de Médecine
11 rue Humann
67000 Strasbourg
France

Laurence Meyer

Université de Strasbourg
Equipe Stéroïdes
Neuromodulateurs et
Neuropathologies
Unité de Physiopathologie et
Médecine Translationnelle
Faculté de Médecine
11 rue Humann
67000 Strasbourg
France

Bayanne Olabi

The Queen's Medical Research
Institute, Endocrinology Unit
Centre for Cardiovascular Science
47 Little France Crescent
Edinburgh EH16 4TJ
UK

Charlotte Oomen

University of Amsterdam
Centre for Neuroscience
Swammerdam Institute of Life
Sciences
Science Park 904, 1098 XF
Amsterdam
The Netherlands

Christine Patte-Mensah

Université de Strasbourg
Equipe Stéroïdes
Neuromodulateurs et
Neuropathologies
Unité de Physiopathologie et
Médecine Translationnelle
Faculté de Médecine
11 rue Humann
67000 Strasbourg
France

Evelyn Perez

Laboratory of Experimental
Gerontology
Neurocognitive Aging Section
National Institute on Aging
Baltimore, MD
USA

Marzia Pesaresi

University of Milan
Department of Endocrinology
Pathophysiology and applied
Biology
Via Balzaretti 9
20133 Milano
Italy

Scarlet Bella Pinnock

University of Cambridge
Cambridge Centre for Brain
Repair
Forvie Site, Robinson Way
Cambridge CB2 0PY
UK

Yanina Revsin

Leiden University
 Division of Medical
 Pharmacology
 Leiden Amsterdam Center for
 Drug Research
 Einsteinweg 55
 2300RA Leiden
 The Netherlands

Przemyslaw (Mike) Sapielha

Harvard Medical School
 Department of Ophthalmology
 300 Longwood Avenue
 Boston, MA
 USA

and

University of Montreal
 Faculty of Medicine
 5415 Assomption Boulevard
 Montreal, Quebec
 Canada

Véronique Schaeffer

Université de Strasbourg
 Equipe Stéroïdes
 Neuromodulateurs et
 Neuropathologies
 Unité de Physiopathologie et
 Médecine Translationnelle
 Faculté de Médecine
 11 rue Humann
 67000 Strasbourg
 France

Marcus D. Schonemann

University of California
 Department of Obstetrics
 Gynecology and Reproductive
 Sciences, The Center for
 Reproductive Sciences
 513 Parnassus Avenue
 San Francisco, CA 94143
 USA

Jonathan Seckl

The Queen's Medical Research
 Institute, Endocrinology Unit
 Centre for Cardiovascular Science
 47 Little France Crescent
 Edinburgh EH16 4TJ
 UK

Armando P. Signore

University of Pittsburgh
 Department of Neurology and
 Center of Cerebrovascular
 Disease Research
 3550 Terrace St.
 Pittsburgh
 PA 15213
 USA

James W. Simpkins

University of North Texas Health
 Science Center, Department of
 Pharmacology & Neuroscience
 Institute for Aging and
 Alzheimer's Disease Research
 Fort Worth, TX
 USA

Meharvan Singh

University of North Texas Health
Science Center, Department of
Pharmacology & Neuroscience
Institute for Aging and
Alzheimer's Disease Research
Center FOR HER
3500 Camp Bowie Blvd.
Fort Worth, TX, 76107
USA

Lois Smith

Harvard Medical School
Department of Ophthalmology
300 Longwood Avenue
Boston, MA
USA

Masatoshi Suzuki

University of Wisconsin Madison
Department of Comparative
Biosciences
School of Veterinary Medicine
2015 Linden Dr. Madison
WI 53706
USA

Marc J. Tetel

Wellesley College
Neuroscience Program
106 Central St.
Wellesley, MA 02481
USA

Kyriaki Thermos

University of Crete
Department of Pharmacology
School of Medicine
71 110 Heraklion
Greece

David Vaudry

University of Rouen
INSERM U982
Place E. Blondel
76821 Mont-Saint-Aignan
France

and

European Institute for Peptide
Research (IFRMP 23)
Place E. Blondel
76821 Mont-Saint-Aignan
France

and

International Laboratory
Samuel de Champlain
76821 Mont-Saint-Aignan
France

and

Regional Platform for Cell
Imaging (PRIMACEN)
IFRMP23
76821 Mont-Saint-Aignan
France

Hubert Vaudry

University of Rouen
INSERM U982
Place E. Blandel
76821 Mont-Saint-Aignan
France

and

European Institute for Peptide
Research (IFRMP 23)
Place E. Blondel
76821 Mont-Saint-Aignan
France

and

International Laboratory
Samuel de Champlain
76821 Mont-Saint-Aignan
France

and

Regional Platform for Cell
Imaging (PRIMACEN)
IFRMP 23
76821 Mont-Saint-Aignan
France

Erno Vreugdenhil

Leiden University, Division of
Medical Pharmacology
Leiden Amsterdam Center for
Drug Research
Einsteinweg 55
2300RA Leiden
The Netherlands

Suping Wang

University of Pittsburgh
Department of Neurology and
Center of Cerebrovascular
Disease Research
3550 Terrace St.
Pittsburgh, PA 15213
USA

Zhongfang Weng

University of Pittsburgh
Department of Neurology and
Center of Cerebrovascular
Disease Research
3550 Terrace St.
Pittsburgh, PA 15213
USA

Kun Don Yi

University of North Texas Health
Science Center, Department of
Pharmacology and Neuroscience,
Institute for Aging and
Alzheimer's Disease Research
Fort Worth, TX
USA

Feng Zhang

University of Pittsburgh
Department of Neurology and
Center of Cerebrovascular
Disease Research
3550 Terrace St.
Pittsburgh, PA 15213
USA

Min Zhou

Ordway Research Institute
Signal Transduction Laboratory
Albany, NY 12208
USA

